Dichotic Listening as a Predictor of Medication Response in Depression - Full Text View

Purpose

This study will recruit 100 depressed patients to test whether the previous finding of an association between treatment response (with treatment groups including placebo, imipramine, and fluoxetine) and preferences of hemispheric laterality in perceptual processing are also found with a different type of commonly used anti-depressant, bupropion.

Condition	Intervention	Phase
Major Depressive Disorder Dysthymia	Drug: escitalopram Drug: bupropion Drug: imipramine	Phase 4

Study Type:	Interventional
Study Design:	Allocation: Non-Randomized Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	Dichotic Listening as a Predictor of Medication Response in Depression

Resource links provided by NLM:

MedlinePlus related topics: Depression

Drug Information available for: Imipramine Imipramine hydrochloride Imipramine pamoate Bupropion hydrochloride Bupropion Citalopram hydrobromide Citalopram Escitalopram oxalate

U.S. FDA Resources

Further study details as provided by New York State Psychiatric Institute:

Primary Outcome Measures:

Hamilton Depression Scale (HAM-D); Fuse Words Test; Nonsense Syllables Test; Complex Tones Test [ Time Frame: 6 mos. ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Clinical Global Impression Scale (CGI); Atypical Depression Diagnostic Scale (ADDS); Derogotis Sexual Performance Scale; Snaith-Hamilton Pleasure Scale; Spielberger State/Trait Anxiety Scale [ Time Frame: 6 mos. ] [ Designated as safety issue: No ]

Enrollment:	25
Study Start Date:	July 2006
Study Completion Date:	August 2011
Primary Completion Date:	August 2011 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: escitalopram escitalopram 10 mg/d for 1 week, then increasing by 10 mg/week if tolerated and not remitted to maximal dose of 40 mg/d	Drug: escitalopram Escitalopram: wk 1: 10 mg/d; wks 2-3: 20 mg/d; wk4: 30 mg/d; wks 5-6: 40 mg/d Other Name: Lexapro.
Experimental: bupropion bupropion XL 150 mg/d for a week, then 300 mg/d for a week and then 450 mg/d; all dose increases if tolerated and not remitted	Drug: bupropion bupropion XL 150 mg/d increasing as tolerated and not remitted by 150 mg/d to maximal dose of 450 mg/d Other Name: Wellbutrin
Experimental: imipramine imipramine 50 mg/d increasing twice weekly by 50 mg/increase to 200 mg/d, then by 50 mg/week to a maximum dose of 300 mg/d; all dose increases if tolerated and not remitted	Drug: imipramine imipramine 50 mg/d increasing twice weekly by 50 mg/increase to 200 mg/d, then 50 mg increase/week to 300 mg/d; all dose increases if tolerated and not remitted Other Name: Tofranil

Detailed Description:

Preliminary data suggest that depressed patients with increased left hemispheric laterality of perceptual processing are unlikely to improve during 6 weeks' treatment with placebo, while being very responsive to either imipramine or fluoxetine. Depressed patients who do not show evidence of poor right hemispheric functioning respond significantly more often to placebo than those with poor right hemispheric functioning , and do not show an advantage of drug over placebo. 100 patients will be tested with verbal and nonverbal dichotic tests, and then treated sequentially with bupropion, escitalopram, and imipramine. Preferential hemisphere for auditory processing will be correlated with treatment outcome.

Eligibility

Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Ages between 18-65
Meets DSM-IV criteria for current Major Depression, Dysthymia or Depression NOS

Exclusion Criteria:

Known Hearing impairment
Active suicidal ideation (history of suicide attempts will be evaluated on a case by case basis).
HAMD>20
Current (past 6 months)alcohol and/or drug abuse or dependence
Medical condition likely to require intervention contraindicated with study medication (e.g., known arrhythmia likely to be exacerbated by Imipramine)
Bipolar I
Psychosis
Non-response to adequate trial of study medication (i.e., > or = 4 weeks on > or = bupropion 300mg/d, escitalopram 30mg/d, or imipramine 200mg/d)
Premenopausal women not using known effective birth control
Not currently depressed (whether considered due to current treatment or not)
History of seizure, seizure disorder, anorexia nervosa, or bulimia
Left-handed -

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00404755

Locations

United States, New York
New York State Psychiatric Institute
New York, New York, United States, 10032

Sponsors and Collaborators

New York State Psychiatric Institute

Investigators

Principal Investigator:	Jonathan W. Stewart, M.D.	New York State Psychiatric Institute
Principal Investigator:	Gerard Bruder, PhD	New York State Psychiatric Institute

More Information

Additional Information:

Depression Evaluation Service official website This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party:	New York State Psychiatric Institute
ClinicalTrials.gov Identifier:	NCT00404755 History of Changes
Other Study ID Numbers:	#5294R, IRB 5294R
Study First Received:	November 28, 2006
Last Updated:	April 26, 2012
Health Authority:	United States: Institutional Review Board

Keywords provided by New York State Psychiatric Institute:

Depression

Additional relevant MeSH terms:

Depression
Depressive Disorder
Dysthymic Disorder
Depressive Disorder, Major
Behavioral Symptoms
Mood Disorders
Mental Disorders
Dexetimide
Citalopram
Imipramine
Bupropion
Antiparkinson Agents
Anti-Dyskinesia Agents
Central Nervous System Agents
Therapeutic Uses

Pharmacologic Actions
Parasympatholytics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Muscarinic Antagonists
Cholinergic Antagonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors

ClinicalTrials.gov processed this record on May 21, 2013